Interpore Cross International
This article was originally published in The Gray Sheet
Firm's Pro Osteon 500 bone graft substitute gains FDA approval for expanded indications in treating cysts and tumors in long bones, both in the metaphysis and the diaphysis. The expanded approval via premarket approval application supplement now allows the firm's domestic sales force, which includes direct reps and agents, to promote Pro Osteon to the orthopedic surgical oncologist, the firm says. The product was approved in October 1992 for use in acute, metaphyseal long bone fractures ("The Gray Sheet" Nov. 9, 1992, I&W-4)...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.